Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,149.50    10.50 (0.92%)
Bid:
1,148.50
Ask:
1,149.50
Spread: 1.00 (0.087%)
Market Cap: £9.76b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Pre Stabilisation Notice

27 May 2026 09:31

RNS Number : 8736F
HSBC Bank plc
27 May 2026
Β 

27th May 2026

Β 

Smith & Nephew plc

Pre Stabilisation Notice

HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities

The securities:

Issuer:

Smith & Nephew plc

Guarantor (if any):

n/a

Aggregate nominal amount:

EUR Benchmark

Description:

Fixed rate 12yr due 3rd Jun 2038

Offer price:

TBC

Other offer terms:

Stabilisation:

Stabilising Manager(s):

HSBC Bank plc

Stabilisation period expected to start on:

27th May 2026

Stabilisation period expected to end no later than:

3rd July 2026

Existence, maximum size & conditions of use of over-allotment facility[1]:

5% of the aggregate nominal amount

Stabilisation Venue(s)

Over the counter (OTC)

Β 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

Β 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Regulation (EU) 2017/1129 (the "Prospectus Regulation") (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Regulation), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

Β 

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

Β 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.


[1] Please note that the existence and the maximum size of any greenshoe option, the exercise period of the greenshoe option and any conditions for exercise of the greenshoe option must also be disclosed, if such option exists. In addition, the exercise of the greenshoe option must be disclosed to the public promptly, together with all appropriate details, including in particular the date of exercise and the number and nature of securities involvedΒ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
STAZZGZKRNRGVZG
Date   Source Headline
27th Jul 20177:00 amRNSHalf-year Report
13th Jul 201711:42 amRNSNotice of Results
12th Jul 20174:44 pmRNSDirector/PDMR Shareholding
4th Jul 20178:04 amRNSDirectorate Change
3rd Jul 201710:56 amRNSTotal Voting Rights
8th Jun 20174:11 pmRNSTransaction in Own Shares
1st Jun 20171:59 pmRNSTotal Voting Rights
23rd May 20174:22 pmRNSTransaction in Own Shares
22nd May 20175:39 pmRNSTransaction in Own Shares
19th May 20175:18 pmRNSTransaction in Own Shares
18th May 20175:25 pmRNSTransaction in Own Shares
18th May 20172:29 pmRNSDirector/PDMR Shareholding
15th May 20171:54 pmRNSTransaction in Own Shares
12th May 20172:18 pmRNSDirector/PDMR Shareholding
11th May 201710:55 amRNSDirector/PDMR Shareholding
5th May 20177:00 amRNSTrading Statement
2nd May 201712:04 pmRNSTotal Voting Rights
26th Apr 20172:05 pmRNSDividend Declaration
11th Apr 20171:04 pmRNSNotice of Results
10th Apr 20174:12 pmRNSDirector/PDMR Shareholding
6th Apr 20174:50 pmRNSResult of AGM
3rd Apr 20173:07 pmRNSTotal Voting Rights
24th Mar 20173:03 pmRNSDirector/PDMR Shareholding
23rd Mar 20171:42 pmRNSAdditional Listing
10th Mar 20174:20 pmRNSDirector/PDMR Shareholding
8th Mar 20179:17 amRNSDirector/PDMR Shareholding
6th Mar 20171:49 pmRNSAnnual Financial Report - Replacement
6th Mar 20171:04 pmRNSAnnual Financial Report
1st Mar 20171:16 pmRNSTotal Voting Rights
21st Feb 20175:44 pmRNSTransaction in Own Shares
20th Feb 20175:46 pmRNSTransaction in Own Shares - Amendment
20th Feb 20175:28 pmRNSTotal Voting Rights
16th Feb 20175:44 pmRNSTransaction in Own Shares
15th Feb 20175:23 pmRNSDirector/PDMR Shareholding
14th Feb 20175:46 pmRNSTransaction in Own Shares
13th Feb 20174:08 pmRNSDirector/PDMR Shareholding
13th Feb 20179:23 amRNSTransaction in Own Shares
9th Feb 20177:05 amRNSDirectorate Change
9th Feb 20177:00 amRNSFinal Results
1st Feb 20176:28 pmRNSBlocklisting Interim Review
1st Feb 20175:28 pmRNSTotal Voting Rights
17th Jan 20175:05 pmRNSDirector/PDMR Shareholding
12th Jan 201712:14 pmRNSDirectorate Change
3rd Jan 20174:47 pmRNSTotal Voting Rights
21st Dec 20165:01 pmRNSNotice of Results
21st Dec 20161:48 pmRNSTransaction in Own Shares
19th Dec 20165:17 pmRNSTransaction in Own Shares
16th Dec 20165:13 pmRNSTransaction in Own Shares
15th Dec 20165:38 pmRNSTransaction in Own Shares
14th Dec 20165:30 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.